Overview

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Tours
Collaborator:
Roche Pharma AG
Treatments:
Citric Acid
Rituximab
Sodium Citrate